Glasdegib (Daurismo)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism from the NCI Drug Dictionary: An orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic activity. Glasdegib appears to inhibit Hh pathway signaling.
Route: PO
Extravasation: n/a

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is established

History of changes in FDA indication

  • 2018-11-21: Initial FDA approval for use in combination with low-dose cytarabine (LDAC), for newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years old or older or who have comorbidities that preclude intensive induction chemotherapy. (Based on BRIGHT AML 1003)

History of changes in EMA indication

  • 2020-06-26: Initial authorization
  • Uncertain date: Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.

Patient Drug Information

Also known as

  • Code name: PF-04449913
  • Brand name: Daurismo